SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-23-035755
Filing Date
2023-07-24
Accepted
2023-07-24 08:35:32
Documents
13
Period of Report
2023-07-23
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ny20009606x6_8k.htm   iXBRL 8-K 32550
2 EXHIBIT 99.1 ny20009606x6_ex99-1.htm EX-99.1 9863
  Complete submission text file 0001140361-23-035755.txt   184176

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA infi-20230723.xsd EX-101.SCH 3853
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE infi-20230723_lab.xml EX-101.LAB 22546
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE infi-20230723_pre.xml EX-101.PRE 16036
7 EXTRACTED XBRL INSTANCE DOCUMENT ny20009606x6_8k_htm.xml XML 4241
Mailing Address 1100 MASSACHUSETTS AVENUE FLOOR 4 CAMBRIDGE MA 02138
Business Address 1100 MASSACHUSETTS AVENUE FLOOR 4 CAMBRIDGE MA 02138 6174531000
INFINITY PHARMACEUTICALS, INC. (Filer) CIK: 0001113148 (see all company filings)

IRS No.: 330655706 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-31141 | Film No.: 231103822
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences